Understanding Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of estrogen receptors, progesterone receptors, and the excess expression of the HER2 protein. TNBC makes up about 10-15% of breast cancer diagnoses and is known for its aggressive nature and higher likelihood of recurrence compared to other breast cancer types. Given its unique biology, treatment options can be limited, making the exploration of immunotherapy a crucial aspect of managing this form of cancer.
The Role of Immunotherapy in Cancer Treatment
Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. It works by stimulating the immune response or by directly targeting cancer cells. In recent years, immunotherapy has shown promising results in various types of cancers, including melanoma and lung cancer, and research has been ongoing to explore its efficacy in TNBC. In 2019, several immunotherapeutic approaches were being studied for TNBC, including checkpoint inhibitors, antibody-drug conjugates, and cancer vaccines.
Identifying Immunotherapy Options in 2019
To find immunotherapy options for TNBC in 2019, patients should start by consulting their oncologist. Oncologists are the best resources for up-to-date treatment options available. Patients can also research clinical trials that are actively enrolling TNBC patients for immunotherapy treatments. Websites such as ClinicalTrials.gov offer a comprehensive database of ongoing studies. Additionally, organizations such as the American Society of Clinical Oncology (ASCO) provide guidelines and information about emerging therapies and clinical trials.
Understanding Clinical Trials
Clinical trials are research studies that test new treatments to determine their safety and effectiveness. They are essential in developing new therapies for TNBC. Patients should familiarize themselves with the inclusion and exclusion criteria for trials to see if they qualify for participation. Discussing the option of clinical trials with the oncologist can provide insight into whether enrolling in a trial is a suitable choice for the patient.
Support and Resources
Finding support from breast cancer organizations can provide patients with resources and information on immunotherapy options. Organizations such as Susan G. Komen and the Breast Cancer Research Foundation have dedicated information and support lines for patients seeking treatment options. Local support groups, both in-person and online, can also be vital sources of information and emotional support during treatment.